Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...

The Freshwater Ecosystems Explorer offers what experts call an unprecedented look at the world’s lakes, rivers and wetlands, ...

Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...

Good morning everyone, it’s Jason Mast, filling in for Ed. Today I’m in Pharmalittle’s New York bureau, sipping a cup poured from a French press gifted to me by my sisters, made from beans ...

Australia’s Therapeutic Goods Administration (TGA) has once again decided against approving Eisai Australia Pty Ltd.’s amyloid beta binder, Leqembi (lecanemab), for treating patients with mild ...

The provided clinical study data demonstrated that patients treated with LEQEMBI showed some slowing in disease progression in some populations compared to those given a placebo, but this was not ...

Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor Lars Lannfelt and his ...

The CHMP’s reaffirmation comes after the EC requested a review of recent safety data in January 2025 ... Lecanemab, also known as Leqembi®, is the product of a strategic alliance between Eisai and ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on ...

Vials of Eisai and Biogen's new Alzheimer's drug Leqembi 34,796 people played the daily Crossword recently. Can you solve it faster than others?34,796 people played the daily Crossword recently.